Effective anti-tumor activity of oxaliplatin encapsulated in transferrin–PEG-liposome

Advanced targeted therapies in cancer: Drug nanocarriers, the future of chemotherapy

“…With respect to immunoliposomes, although many preclinical studies can be found in the literature [24,215,275,276] and a few clinical trials are in progress [18,75,[277][278][279] an siRNA that targets PKN3 [18,286], or TKM-PLK1 that includes siRNA against PLK1 for the treatment of neuroendocrine tumors and adrenocortical carcinomas (phase I/II clinical trials) [283,287,288]. The phase I liposomic formulation SGT-53 includes plasmidic DNA that expresses the tumor suppressor gene p53 to treat solid tumors [280,289].…”

Pharmaceutical properties of supramolecular assembly of co-loaded cardanol/triazole-halloysite systems

“…Over 80% of liver cancer patients are diagnosed with hepatocellular carcinoma, which is resistant to most conventional chemotherapeutic agents (Wilson et al, 2012). Moreover, the use of chemoprevention agents is typically associated with side effects that lead to the destruction of normal tissues, such as those of the digestive, hematopoietic and nervous systems (Meyskens and Gerner, 1999;Suzuki et al, 2008;Florea and Büsselberg, 2011). The development of drugs that specifically target tumor cells, but not normal cells, represents a common goal.…”

Dual-ligand modification of PEGylated liposomes shows better cell selectivity and efficient gene delivery

“…The negative effect of PEGylation on the target site is called the PEG dilemma, which hampers the practical application of drugs or other macromolecules, when the use of LPs is being considered [3,4]. To overcome this problem, various ligands such as transferrin [5], folic acid [6], peptides [7,8] or antibodies [9] are added at the terminal ends of PEG moieties to produce active targeting PEG-LPs. Anticancer drugs that are encapsulated within ligand modified PEG-LPs demonstrate increased binding, improved cytotoxicity and, in many cases, improved therapeutic efficacy, compared with PEG-LPs [10][11].…”